The diagnosis is never the whole story.
Living with an autoimmune condition means living with it every day. We compound formulations that give physicians more ways to care for the whole patient.
For patients whose condition doesn't always fit neatly into a diagnosis
Many people with autoimmune conditions spend years looking for answers. They have good days and hard days, and much of what they live with is invisible to everyone around them: the fatigue, the flares, the plans canceled at the last minute.
Every patient's immune picture is different. Compounding lets physicians prescribe in the strengths, forms, and combinations that fit the individual, so care can reflect the whole person, not just a label.
We work with functional medicine physicians, rheumatologists, naturopathic physicians, and other specialists who take a closer look at immune function, and who want a compounding partner who meets their patients where they are.
Hashimoto's & Graves' disease
Lupus
Multiple sclerosis (MS)
Rheumatoid arthritis
Crohn's disease & ulcerative colitis
Psoriasis
Conditions
For physicians caring for patients with complex immune challenges, from cancer and autoimmune disease to the conditions that don’t always fit neatly into a diagnosis.
We work with physicians who take a closer look at immune function and the role it may play in their patients’ care. That includes integrative and naturopathic oncologists, functional medicine physicians, rheumatologists, and other specialists who are bringing a research informed perspective to complex cases.
Whether a patient is navigating cancer, an autoimmune condition, or both, their physician needs a compounding pharmacy that can meet them there.
What we compound
-
Capsules and oral solutions at 1.5 mg, 3 mg, and 4.5 mg, prepared to the prescription. Physicians prescribe LDN off-label for a range of autoimmune conditions.
-
Two compounds researchers have explored in cancer and autoimmune models, available individually or as a single combination capsule at prescriber-specified strength. Oncology-range dosing requires compounding.
-
LDN with Ivermectin, LDN with Mebendazole, or all three together, or all three together, in one capsule at prescriber-specified strength. Our full formulary is available to registered providers.
Compounding is most powerful when the pharmacy thinks about the patient the way the physician does.
-
Twenty years of specialty compounding across complex, patient-specific formulations.
-
Pharmacists available for clinical consultation, not just order fulfillment.
-
±5% potency tolerance, USP 795/797/800, independent third-party testing.
-
Certificate of Compliance with every batch, sourcing and formulation documentation on request.
GenoGenRx compounds the Precision Immune Protocol to your specification. LDN, Ivermectin, and Mebendazole, individually or in combination, at strengths not commercially available.
Precision immune care starts here
Help patients create a plan built on their own biology.
Sign up today for a free GLP-1 Genetic Test Kit.
Selected Published Research
Low-Dose Naltrexone
Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone
Berkson et al. · Integrative Cancer Therapies · 2007 · Case report
Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
Ciwun et al. · Cancers · 2024 · Review
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer
Berkson et al. · Integrative Cancer Therapies · 2009 · Case series
Naltrexone at low doses (LDN) and its relevance to cancer therapy
Liu & Dalgleish · Expert Review of Anticancer Therapy · 2022 · Review
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol
Berkson et al. · Integrative Cancer Therapies · 2006 · Case report
Ivermectin & Mebendazole
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Tang et al. · Pharmacological Research · 2020 · Review
Ivermectin as an inhibitor of cancer stem‑like cells
Dominguez-Gomez et al. · Molecular Medicine Reports · 2018 · Preclinical
Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
Baghli et al. · Journal of Orthomolecular Medicine · 2024 · Protocol
Cancer Care: Approach to the Use of Repurposed Drugs and Nutraceuticals in Patients With Cancer
Marik · Independent Medical Alliance · 2026 · Clinical guidance
Mebendazole or Fenbendazole
CancerChoices · Health professional section · 2025 · Summary
Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer
Williamson et al. · Oncotarget · 2021 · Study
Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
Hulscher et al. · Anticancer Research · 2026 · Observational study
Research is provided for educational purposes for licensed healthcare professionals.